DDInter980 DDInter1676
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Isavuconazonium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loratadine
Isavuconazonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Isavuconazonium {u} may lead to a major life threatening interaction when taken with {v} Cobimetinib
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Isavuconazonium may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Loratadine
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Isavuconazonium may lead to a major life threatening interaction when taken with Apalutamide
Isavuconazonium may lead to a major life threatening interaction when taken with Cobimetinib